Core Insights - MaxCyte has signed a strategic platform license agreement with Adicet Bio to utilize its Flow Electroporation® technology and ExPERT™ platform for developing gamma delta T cell therapies [1][2] - Adicet Bio aims to enhance its manufacturing capabilities for allogeneic gamma delta T cell therapies, which are designed for cancer and autoimmune diseases [3][4] Company Overview - MaxCyte is a leading cell-engineering company focused on advancing cell-based therapeutics through its Flow Electroporation® technology and ExPERT™ platform [5] - The company has over 25 years of experience in cell engineering, providing tools and services that support the development of safe and effective treatments [5] Agreement Details - The agreement grants Adicet Bio non-exclusive rights for research, clinical, and commercial use of MaxCyte's technologies, while MaxCyte will receive licensing fees and program-related revenue [2] - MaxCyte's ExPERT™ platform is noted for its high transfection efficiency, cell viability, and scalability, which are essential for developing next-generation cell therapies [4]

Core Insights - MaxCyte, Inc. has signed a Strategic Platform License Agreement (SPL) with Anocca AB to utilize its Flow Electroporation technology and ExPERT™ platform for the development of TCR-T cell therapies [1][2] - Anocca AB will gain non-exclusive rights for research, clinical, and commercial applications of MaxCyte's technology, while MaxCyte will receive annual licensing fees and program-related revenue [2] - Anocca has recently achieved GMP compliance certification and a manufacturing license for its cell therapy production facility, with its lead program targeting advanced pancreatic cancer currently in clinical development [3] Company Overview - MaxCyte is focused on cell engineering and aims to advance the discovery, development, and commercialization of next-generation cell therapies [4] - The company offers Flow Electroporation technology and SeQure DX™ gene editing risk assessment services, which facilitate precise and scalable cell engineering [4] - MaxCyte has over 25 years of experience in advancing cell engineering and is committed to shaping the future of medicine [4]

Company Overview - MaxCyte, Inc. is a leading company focused on cell engineering, providing platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics [1][3] - The company has over 25 years of expertise in building best-in-class platforms and innovating solutions for the cell therapy market [3] Financial Results Announcement - MaxCyte will release its financial results for the first quarter of 2025 after the U.S. market closes on May 7, 2025 [1] - A conference call to discuss these financial results will be hosted by company management at 4:30 p.m. Eastern Time on the same day [1] Conference Call Registration - Investors interested in the conference call must register online, with a recommendation to do so at least a day in advance [2] - A live and archived webcast of the event will be available on the MaxCyte website [2]